Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Stéphanie Bolle is active.

Publication


Featured researches published by Stéphanie Bolle.


International Journal of Radiation Oncology Biology Physics | 2016

Efficacy and Safety of Adjuvant Proton Therapy Combined With Surgery for Chondrosarcoma of the Skull Base: A Retrospective, Population-Based Study

L. Feuvret; Stefano Bracci; V. Calugaru; Stéphanie Bolle; Hamid Mammar; Ludovic De Marzi; Damien Bresson; Jean-Louis Habrand; Jean-Jacques Mazeron; Rémi Dendale; Georges Noel

PURPOSE Chondrosarcoma is a rare malignant tumor of the cartilage affecting young adults. Surgery, followed by charged-particle irradiation, is considered the reference standard for the treatment of patients with grade I to II skull base chondrosarcoma. The present study was conducted to assess the effect of the quality of surgery and radiation therapy parameters on local control (LC) and overall survival (OS). METHODS AND MATERIALS From 1996 to 2013, 159 patients (median age 40 years, range 12-83) were treated with either protons alone or a combination of protons and photons. The median total dose delivered was 70.2 Gy (relative biologic effectiveness [RBE]; range 67-71). Debulking and biopsy were performed in 133 and 13 patients, respectively. RESULTS With a median follow-up of 77 months (range 2-214), 5 tumors relapsed based on the initial gross tumor volume. The 5- and 10-year LC rates were 96.4% and 93.5%, respectively, and the 5- and 10-year OS rates were 94.9% and 87%, respectively. A total of 16 patients died (13 of intercurrent disease, 3 of disease progression). On multivariate analysis, age <40 years and primary disease status were independent favorable prognostic factors for progression-free survival and OS, and local tumor control was an independent favorable predictor of OS. In contrast, the extent of surgery, dosimetric parameters, and adjacent organs at risk were not prognostic factors for LC or OS. CONCLUSIONS Systematic high-dose postoperative proton therapy for skull base chondrosarcoma can achieve a high LC rate with a low toxicity profile. Maximal safe surgery, followed by high-dose conformal proton therapy, is therefore recommended.


Neurology | 2013

De novo arteriovenous malformation after brain radiotherapy for medulloblastoma in a child

Bertrand Mathon; Thomas Blauwblomme; Stéphanie Bolle; Christelle Dufour; Olivier Nagarra; Francis Brunelle; Stéphanie Puget

A 5-year-old boy was operated on for a non-metastatic medulloblastoma of the fourth ventricle (figure 1). Chemotherapy and bifractionated craniospinal radiotherapy were administered. Four years later, T1-weighted MRI with contrast revealed abnormal vessels in the right sylvian fissure that gradually increased during follow-up; angiography confirmed an arteriovenous malformation (AVM) (figure 2). Even though it was asymptomatic, its location and growth prompted us to treat (embolization then excision of the residual nidus). This very rare case of supposed radiation-induced AVM suggests that when abnormal vasculature imaging occurs in follow-up1,2 further investigation with angiography is warranted, with consideration of further treatment.


Strahlentherapie Und Onkologie | 2015

Long-term side effects of radiotherapy for pediatric localized neuroblastoma

A. Ducassou; Marion Gambart; Caroline Munzer; Laetitia Padovani; Christian Carrie; Daphne A. Haas-Kogan; Valérie Bernier-Chastagner; Charlotte Demoor; L. Claude; Sylvie Helfre; Stéphanie Bolle; J. Leseur; Aymeri Huchet; Hervé Rubie; Dominique Valteau-Couanet; Gudrun Schleiermacher; Carole Coze; Anne-Sophie Defachelles; Aurélien Marabelle; Stéphane Ducassou; Christine Devalck; Virginie Gandemer; Martine Munzer; Anne Laprie

Introduction: Neuroblastoma (NB) is the most frequent indication for extracranial pediatric radiotherapy. As long-term survival of high-risk localized NB has greatly improved, we reviewed treatment-related late toxicities in pediatric patients who received postoperative radiotherapy (RT) for localized NB within two French prospective clinical trials: NB90 and NB94. Patients and methods: From 1990–2000, 610 children were enrolled. Among these, 35 were treated with induction chemotherapy, surgery, and RT. The recommended RT dose was 24 Gy at ≤ 2 years, 34 Gy at > 2 years, ± a 5 Gy boost in both age groups. Results: The 22 patients still alive after 5 years were analyzed. The median follow-up time was 14 years (range 5–21 years). Late effects after therapy occurred in 73 % of patients (16/22), within the RT field for 50 % (11/22). The most frequent in-field effects were musculoskeletal abnormalities (n = 7) that occurred only with doses > 31 Gy/1.5 Gy fraction (p = 0.037). Other effects were endocrine in 3 patients and second malignancies in 2 patients. Four patients presented with multiple in-field late effects only with doses > 31 Gy. Conclusion: After a median follow-up of 14 years, late effects with multimodality treatment were frequent. The most frequent effects were musculoskeletal abnormalities and the threshold for their occurrence was 31 Gy.


Radiotherapy and Oncology | 2017

Patterns of failure after radiotherapy for pediatric patients with intracranial ependymoma

F. Tensaouti; Anne Ducassou; Léonor Chaltiel; Stéphanie Bolle; Xavier Muracciole; Bernard Coche-Dequeant; Claire Alapetite; V. Bernier; L. Claude; S. Supiot; Aymeri Huchet; Christine Kerr; Elisabeth Le Prisé; Anne Laprie

PURPOSE To investigate the patterns of failure after radiotherapy for pediatric intracranial ependymoma and their correlation with dose parameters. METHODS Between 2000 and 2013, 206 patients were treated in France. MRI scans at relapse were registered to the original planning CTs for topographic analysis of failure patterns. To compare relapse patients (RP) with non relapse patients (NRP), several dose parameters were derived from dose volume histograms. RESULTS Over a median follow-up of 53.8months, 84 patients presented with relapse. Topographic analysis showed 50 patients with local relapse in the radiation field, 6 in the edge of field, 6 locoregional outside the field, 10 in the spine, 5 supratentorial and 7 local and distant. The median coverage, target coverage and homogeneity indices did not differ significantly between RP and NRP. The median volume of in-field relapse was 1.25cc [0.11, 27], with a median dose of 57.83Gy [50.04, 61.69]. CONCLUSIONS Local relapse in the tumor bed and the higher dose regions was the predominant pattern of failure. Improving coverage of the target volume and increasing the dose to the high radioresistant regions, taking into consideration other clinical and biological pronostic factors, may be an effective way of reducing local failures.


Strahlentherapie Und Onkologie | 2015

Long-term side effects of radiotherapy for pediatric localized neuroblastoma : results from clinical trials NB90 and NB94.

A. Ducassou; Marion Gambart; Caroline Munzer; Laetitia Padovani; Christian Carrie; Daphne A. Haas-Kogan; Bernier-Chastagner; Charlotte Demoor; L. Claude; Sylvie Helfre; Stéphanie Bolle; J. Leseur; Aymeri Huchet; Hervé Rubie; Dominique Valteau-Couanet; Gudrun Schleiermacher; Carole Coze; Anne-Sophie Defachelles; Aurélien Marabelle; Stéphane Ducassou; Christine Devalck; Gandemer; Martine Munzer; Anne Laprie

Introduction: Neuroblastoma (NB) is the most frequent indication for extracranial pediatric radiotherapy. As long-term survival of high-risk localized NB has greatly improved, we reviewed treatment-related late toxicities in pediatric patients who received postoperative radiotherapy (RT) for localized NB within two French prospective clinical trials: NB90 and NB94. Patients and methods: From 1990–2000, 610 children were enrolled. Among these, 35 were treated with induction chemotherapy, surgery, and RT. The recommended RT dose was 24 Gy at ≤ 2 years, 34 Gy at > 2 years, ± a 5 Gy boost in both age groups. Results: The 22 patients still alive after 5 years were analyzed. The median follow-up time was 14 years (range 5–21 years). Late effects after therapy occurred in 73 % of patients (16/22), within the RT field for 50 % (11/22). The most frequent in-field effects were musculoskeletal abnormalities (n = 7) that occurred only with doses > 31 Gy/1.5 Gy fraction (p = 0.037). Other effects were endocrine in 3 patients and second malignancies in 2 patients. Four patients presented with multiple in-field late effects only with doses > 31 Gy. Conclusion: After a median follow-up of 14 years, late effects with multimodality treatment were frequent. The most frequent effects were musculoskeletal abnormalities and the threshold for their occurrence was 31 Gy.


Reports of Practical Oncology & Radiotherapy | 2016

Chordoma in children: Case-report and review of literature

J.-L. Habrand; Jean Datchary; Stéphanie Bolle; A. Beaudré; Ludovic De Marzi; Kevin Beccaria; Dinu Stefan; Jacques Grill; Rémi Dendale

We report an exceptional case of a very late local failure in a 9-year-old boy presenting with a chordoma of the cranio-cervical junction. The child was initially treated with a combination of surgical resection followed by high dose photon-proton radiation therapy. This aggressive therapy allowed a 9-year remission with minimal side-effects. Unfortunately, he subsequently presented with a local failure managed with a second full-dose course of protons. The child died one year later from local bleeding of unclear etiology.


Frontiers in Oncology | 2017

Relationships between Regional Radiation Doses and Cognitive Decline in Children Treated with Cranio-Spinal Irradiation for Posterior Fossa Tumors

Elodie Doger de Spéville; Charlotte Robert; Martin Perez-Guevara; Antoine Grigis; Stéphanie Bolle; Clemence Pinaud; Christelle Dufour; A. Beaudré; Virginie Kieffer; Audrey Longaud; Jacques Grill; Dominique Valteau-Couanet; Eric Deutsch; Dimitri Lefkopoulos; Catherine Chiron; Lucie Hertz-Pannier; Marion Noulhiane

Pediatric posterior fossa tumor (PFT) survivors who have been treated with cranial radiation therapy often suffer from cognitive impairments that might relate to IQ decline. Radiotherapy (RT) distinctly affects brain regions involved in different cognitive functions. However, the relative contribution of regional irradiation to the different cognitive impairments still remains unclear. We investigated the relationships between the changes in different cognitive scores and radiation dose distribution in 30 children treated for a PFT. Our exploratory analysis was based on a principal component analysis (PCA) and an ordinary least square regression approach. The use of a PCA was an innovative way to cluster correlated irradiated regions due to similar radiation therapy protocols across patients. Our results suggest an association between working memory decline and a high dose (equivalent uniform dose, EUD) delivered to the orbitofrontal regions, whereas the decline of processing speed seemed more related to EUD in the temporal lobes and posterior fossa. To identify regional effects of RT on cognitive functions may help to propose a rehabilitation program adapted to the risk of cognitive impairment.


British Journal of Radiology | 2016

Prognostic and predictive values of diffusion and perfusion MRI in paediatric intracranial ependymomas in a large national study

F. Tensaouti; Anne Ducassou; Léonor Chaltiel; Annick Sevely; Stéphanie Bolle; Xavier Muracciole; Bernard Coche-Dequant; Claire Alapetite; S. Supiot; Aymeri Huchet; V. Bernier; L. Claude; Anne-Isabelle Bertozzi-Salamon; Samuel Liceaga; Jean Albert Lotterie; Patrice Péran; Pierre Payoux; Anne Laprie

OBJECTIVE To assess the relative cerebral blood volume (rCBV) and apparent diffusion coefficient (ADC) derived, respectively, from perfusion and diffusion pre-operative MRI of intracranial ependymomas and their predictive and prognostic values. METHODS Pre-operative MRI and clinical data for intracranial ependymomas diagnosed between January 2000 and December 2013 were retrospectively retrieved from a web-based national database. MRI data included diffusion (62 patients) and perfusion (20 patients) MRI. Patient age, histopathological diagnosis, tumour location, ADC, relative ADC (rADC) and rCBV were considered as potential factors in a survival analysis. Survival rates were estimated using the Kaplan-Meier method. Univariate analyses were performed using the log-rank test to compare groups. We also performed a multivariate analysis, applying the Cox proportional hazards model. RESULTS ADC and rADC values within hypointense regions differed significantly between grades II and III (p = 0.01). The 75th percentile of ADC within hypointense regions and the 25th percentile of rCBV within non-enhancing lesions were prognostic of disease-free survival (p = 0.004, p = 0.05). A significant correlation was found between the 75th percentile of rCBV and the 25th percentile of rADC (p = 0.01) in enhancing regions of grade-III tumours. CONCLUSION Pre-operative rADC and rCBV could be used as prognostic factors for clinical outcome and to predict histological grade in paediatric ependymomas. ADVANCES IN KNOWLEDGE Prognostic value of diffusion and perfusion MRI in paediatric ependymoma was found and may play a role in the prognostic classification of patients in order to design more tailored treatment strategies.


Reports of Practical Oncology & Radiotherapy | 2016

Reprint of “Chordoma in children: Case-report and review of literature” ☆

J.-L. Habrand; Jean Datchary; Stéphanie Bolle; A. Beaudré; Ludovic De Marzi; Kevin Beccaria; Dinu Stefan; Jacques Grill; Rémi Dendale

We report an exceptional case of a very late local failure in a 9-year-old boy presenting with a chordoma of the cranio-cervical junction. The child was initially treated with a combination of surgical resection followed by high dose photon-proton radiation therapy. This aggressive therapy allowed a 9-year remission with minimal side-effects. Unfortunately, he subsequently presented with a local failure managed with a second full-dose course of protons. The child died one year later from local bleeding of unclear etiology.


Radiotherapy and Oncology | 2018

Proton beam therapy for skull base chordomas in 106 patients: A dose adaptive radiation protocol

Vivien Fung; V. Calugaru; Stéphanie Bolle; Hamid Mammar; Claire Alapetite; Philippe Maingon; Ludovic De Marzi; S. Froelich; Jean-Louis Habrand; Rémi Dendale; Georges Noel; L. Feuvret

BACKGROUND AND PURPOSE To evaluate clinical results and safety of a dose adaptive protocol based on tumor volume coverage and critical structure constraints, for the treatment of skull base chordomas. MATERIAL AND METHODS Between May 2006 and October 2012, 106 patients with skull base chordoma were treated by combined photon and proton irradiation. Prescribed dose levels were 68.4, 70.2, 72 and 73.8 Gy(RBE) in once daily fractionation of 1.8 Gy(RBE). Dose level and dosimetric constraints to organs at risk depended on postoperative residual Gross Tumor Volume (GTV) coverage. Local control (LC) and overall survival (OS) were evaluated using the Kaplan-Meier method. RESULTS With a median follow-up of 61 months, the 2-year, 4-year, and 5-year LC rates were 88.6%, 78.3%, and 75.1%, respectively. GTV > 25 mL (p = 0.034, HR = 2.22; 95%CI 1.06-4.62) was an independent unfavorable prognostic factor of LC. The 2-year, 4-year, and 5-year OS rates were 99%, 90.2%, and 88.3%, respectively. Grade 3-5 late toxicity was observed in 7 patients, resulting in 93% 5-year freedom from high-grade toxicity. CONCLUSIONS This study suggests that the probability of LC of skull base chordomas depends on postoperative GTV. The dose adaptive protocol achieves acceptable local control. Future studies should investigate whether further dose escalation to doses in excess of 74 Gy(RBE) would achieve better results.

Collaboration


Dive into the Stéphanie Bolle's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anne Laprie

University of Toulouse

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

S. Supiot

University of Toronto

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge